
Partners develop oral ketamine-based antidepressant for home use
MIRA Pharmaceuticals and MIRALOGX have formed a new partnership to develop and commercialise oral ketamine analog Ketamir-2, hoping to change the landscape of depressive disorder treatments. Ketamir-2 is a patent-pending compound under investigation to potentially deliver ultra-rapid antidepressant effects as early as four hours after dosing. Read More
